Mikael Åberg

Head of Unit: Affinity Proteomics, Uppsala University

Keywords
, , , , , , , , ,
Key Publications
Complement activation characterizes a high mortality subgroup in pulmonary embolism: An observational proteomic study.
Thrombosis research, 2026
Read more
Vaccination-first immune priming shapes a sustained mRNA vaccine-induced IgG4 class switch that associates with SARS-CoV-2 breakthrough infection risk.
Scientific reports, 2026
Read more
Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults.
Vaccine, 2026
Read more
The role of mucosal IgA in protection against influenza A H1N1 virus infection in a real-world setting.
EBioMedicine, 2026
Read more
Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.
EBioMedicine, 2026
Read more
SciLifeLab / Contact / Mikael Åberg

We specialize in scalable affinity-based proteomics for biomarker discovery, molecular biosciences and precision medicine. Our technologies enable high-throughput protein analysis and advanced proteomic solutions for research and clinical applications.

Group Members:

Mikael Åberg, Docent, Head of unit
Cecilia Kriegholm, MSc Lab Coordinator low plex
Johanna Svensson, MSc, Lab Coordinator high plex
Ingrid Berlin Jones, MSc
Ylva Nätterkvist, MSc
Eléna Coulier, MSc
Ann-Charlotte Rönn, PhD
Radiosa Galini, PhD
Hongxing Zhao, PhD
Liza Löf, PhD
Avinash Khandagale, PhD
Yuzhen Dan, PhD

Last updated: 2026-08-17

Content Responsible: David Gotthold(david.gotthold@scilifelab.se)